{"name":"Prime Medicine","slug":"prime-medicine","ticker":"PRME","exchange":"NASDAQ","domain":"primemedicine.com","description":"Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.","hq":"Cambridge, MA","founded":0,"employees":"146","ceo":"Keith Gottesdiener","sector":"Gene Editing / Genetic Medicine","stockPrice":3.17,"stockChange":-0.1,"stockChangePercent":-3.06,"marketCap":"$572M","metrics":{"revenue":4632000,"revenueGrowth":-41.1,"grossMargin":0,"rdSpend":160636000,"netIncome":-201142000,"cash":135496992,"dividendYield":0,"peRatio":-3.6,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"PM-101 patent cliff ($0.0B at risk)","drug":"PM-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"PRME Announces FDA Clearance for PM-101 Clinical Trial","summary":"Prime Medicine received FDA clearance to initiate a Phase 1 clinical trial for PM-101, its lead gene editing therapy.","drugName":"PM-101","sentiment":"positive"},{"date":"2023-11-15","type":"earnings","headline":"PRME Reports Q3 2023 Earnings: Revenue Up 25% YoY","summary":"Prime Medicine reported a 25% increase in revenue for the third quarter of 2023, driven by progress in its clinical pipeline.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQTlI1UHJkQmNYZkEzRzJET3BlWlJWTjREdm4wTE9CZGVqOTVpNm5qSmFyMXdud2lYbl9mS19ubHdwdDZxMGZYYTQzbllyTHVJdDhST3FsYkxtUV92RHFPZ3NBaGlfZG0wRDV2cEZ2VVNNZS1MVUU3c19KbnVudDNyUDVXVWtnekxFZlltUUs4YVhzUXlTRU9FRzIwemFCQWpFOXc?oc=5","date":"2026-03-08","type":"pipeline","source":"Finviz","summary":"Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway - Finviz","headline":"Prime Medicine (PRME) Focuses on Liver Franchise With $191.4M Cash Runway","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-04","type":"earnings","source":"simplywall.st","summary":"Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives - simplywall.st","headline":"Prime Medicine (PRME) Quarterly Loss Near US$50 Million Reinforces Bearish Community Narratives","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxOQmVfQkpPNUptbmRzRFcweVNJUDNMN3NKZDRYOS1FQnRGVzBNRUVTT3JqQzdVY050V1AyRTJNSVhHem1QamI5dFk4LUJwWm43TkFEYVVKV2NfWG9ZS0N6STRieVkyekFDX242dmVoY2xicjd3d3lTRXV0c004UHBZVnpMNmFsYXFob1UwVXhDMnVWVnMybWprSS1aZG9lbjYwWHdhTzFzT0NuTFhTbDc4T2ZZb3Awci14RmpseEpYS0JGVFF6cDJXZUhYei1MUnFCNkN4aWY4VUpvdmdqZ1E5bUFn0gHnAUFVX3lxTE85NExFLTB1a1JpWWgzbjdhQjl3ekxpZ0FwNDNERGR1VjdCUEFHY0VXVmZsSHBnYkNVaFIzVzZMclJ5WlNCN0xpNlR4blptNk1mYnhlaXpZWUswNGdBT19mQXlGaU5SOHFHTkp3Ym9YeHRSOWQ2cEZIU24zcHN3elNTY2FRd0pSUmJteGVPcXNIY3lxSHk5akFDTjQ1RFpZRDltWTdRbndkMVJKTzR1M21kNTRUVnNLcU5mZTdQcUJnUEFJbU4tSUlQT0hlb0oxaFZKUXp5WXRKbGhTV0VtWDVBdGctVFBjbw?oc=5","date":"2026-01-31","type":"pipeline","source":"simplywall.st","summary":"Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st","headline":"Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although lon","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPNEVTNng3TkdFaWY1SlM5Y29meFkxMVZKZE1EQnUzV014Z0o0YWZmMDZtOVFVajhjTzBNM0ZhQUtvdkhpWjVZcThuNUhaSUNOc196NXNSMDhiXzBZN29LdGlWU2RIZ3VVNnBSVUt1cUY4TTJHeURYMmtQUzZGNU9iNEFXVFpOTzRkQ1lNdXBwLU43TldDVjNpZmVYUmRxc1ZVZXRoRHQzYjl1bkk?oc=5","date":"2026-01-02","type":"pipeline","source":"PR Newswire","summary":"Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - PR Newswire","headline":"Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-09","type":"deal","source":"simplywall.st","summary":"Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying - simplywall.st","headline":"Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE9UZ0RlVmtzZnZYVHRVdlNRWnVoaDZvcjJweEoydm9KV2ZtZm0td2V5aU5vS2xyUTk3WGtXeHpnaThBWUY1cWpGcEo2aWpaX3lxN0drOHlVR2xlS2Vp?oc=5","date":"2025-11-14","type":"pipeline","source":"Finimize","summary":"Prime Medicine Bets On Gene Editing’s Next Big Leap - Finimize","headline":"Prime Medicine Bets On Gene Editing’s Next Big Leap","sentiment":"neutral"},{"date":"2025-11-07","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-11-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQb2ZXSTVyUFJsTklVZTliQXJiZk1nYVZOMjNrMWFoN1I2bGpZQUxfamROX3h6S1ZBZy1DSzhkcnFScG9yQTJKMXBHamFzRi1yU2d3VFdLWWRhV1loV2Rwa3RMOTcxb2JqdmlCenN5OFNDbTBENUVpUFpydjZFSjdCVFRVSFdCMF8xRzVZekFCTWk3R2hCajRtU3BLa0hSa2UzdzZ3YmpkR0VnOXV6MndyMFBUa3VVQ28?oc=5","date":"2025-09-23","type":"pipeline","source":"Seeking Alpha","summary":"Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now (PRME) - Seeking Alpha","headline":"Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now (PRME)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNc1ZybXNqVnFxUGhoQ2dNVEtwQUpjVF9ybWpfazI0RWtzaFlYelczby16RU9nVHlKR1Y1S1dzMF9VdXNnMDBtQnJJWGJlOHJ3N1JQajI1aHlqQVo1czhxVEdyM01qNE5lXzJYTmVnWnNWOHVtZEVpSGliLUJZMlJyYkJLVzNjUWo3YWE1b21SNEIwYVJqZThlcDNfM3EwRV9qUWFlcGhsZVQ2WWJ1UURkcldjU0MzdE45?oc=5","date":"2025-09-22","type":"trial","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Data, Big Name Investors Drive Prime Medicine Stock Surge - Genetic Engineering and Biotechnology News","headline":"StockWatch: Data, Big Name Investors Drive Prime Medicine Stock Surge","sentiment":"neutral"},{"date":"2025-09-08","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE1XN0dfV0xrcEdFd3dfdFNsV2pjdERvOElWVzM5OWxsdHhWUi1TM195QU9Jc3NnRVptUEJ1akFKRUhnVjZEeXdKQzZmZEQxSUZESmNxNmx4aGpVUQ?oc=5","date":"2025-09-03","type":"pipeline","source":"MarketBeat","summary":"Prime Medicine (PRME) Stock Price, News & Analysis - MarketBeat","headline":"Prime Medicine (PRME) Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"PM-101","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Editas Medicine (EDIT)","CRISPR Therapeutics (CRSP)","Intellia Therapeutics (NTLA)"],"therapeuticFocus":["Genetic Diseases","Rare Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":4632000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":4632000,"period":"2025-12-31"},{"value":2983000,"period":"2024-12-31"},{"value":2983000,"period":"2024-12-31"},{"value":0,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":160636000,"rdSpendHistory":[{"period":"2025-12-31","value":160636000},{"period":"2024-12-31","value":155289000},{"period":"2023-12-31","value":147905000},{"period":"2022-12-31","value":86725000}],"sgaSpend":52346000,"operatingIncome":-208350000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-208350000},{"period":"2024-12-31","value":-202467000},{"period":"2023-12-31","value":-191292000},{"period":"2022-12-31","value":-116544000}],"netIncome":-201142000,"netIncomeHistory":[{"period":"2025-12-31","value":-201142000},{"period":"2024-12-31","value":-195882000},{"period":"2023-12-31","value":-198133000},{"period":"2022-12-31","value":-121821000}],"eps":-1.35,"epsHistory":[{"period":"2025-12-31","value":-1.35},{"period":"2024-12-31","value":-1.65},{"period":"2023-12-31","value":-2.18},{"period":"2022-12-31","value":-4.19}],"cash":63032000,"cashHistory":[{"period":"2025-12-31","value":63032000},{"period":"2024-12-31","value":182476000},{"period":"2023-12-31","value":41574000},{"period":"2022-12-31","value":187620000}],"totalAssets":342733000,"totalLiabilities":221865000,"totalDebt":116427000,"equity":120868000,"operatingCashflow":-162564000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-162564000},{"period":"2024-12-31","value":-122865000},{"period":"2023-12-31","value":-165412000},{"period":"2022-12-31","value":-131827000}],"capex":-4531000,"capexHistory":[{"period":"2025-12-31","value":-4531000},{"period":"2024-12-31","value":-7294000},{"period":"2023-12-31","value":-8724000},{"period":"2022-12-31","value":-16095000}],"freeCashflow":-167095000,"dividendsPaid":null,"buybacks":null,"employees":146,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":14737000,"ebit":-48608000,"ebitda":-46732000,"period":"2025-12-31","revenue":838000,"epsBasic":null,"netIncome":-46079000,"rdExpense":34709000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-48608000},{"sga":11208000,"ebit":-53973000,"ebitda":-52092000,"period":"2025-09-30","revenue":1225000,"epsBasic":-0.32,"netIncome":-50582000,"rdExpense":43990000,"epsDiluted":-0.32,"grossProfit":null,"operatingIncome":-53973000},{"sga":13117000,"ebit":-53377000,"ebitda":-51513000,"period":"2025-06-30","revenue":1115000,"epsBasic":-0.41,"netIncome":-52591000,"rdExpense":41375000,"epsDiluted":-0.41,"grossProfit":null,"operatingIncome":-53377000},{"sga":13284000,"ebit":-52392000,"ebitda":-50692000,"period":"2025-03-31","revenue":1454000,"epsBasic":-0.4,"netIncome":-51890000,"rdExpense":40562000,"epsDiluted":-0.4,"grossProfit":null,"operatingIncome":-52392000},{"sga":12301000,"ebit":-44222000,"ebitda":-42505000,"period":"2024-12-31","revenue":2183000,"epsBasic":null,"netIncome":-42276000,"rdExpense":34104000,"epsDiluted":null,"grossProfit":null,"operatingIncome":-44222000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.44,"netIncome":null,"rdExpense":null,"epsDiluted":-0.44,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":3.17,"previousClose":3.27,"fiftyTwoWeekHigh":6.94,"fiftyTwoWeekLow":1.11,"fiftyTwoWeekRange":"1.11 - 6.94","fiftyDayAverage":3.6,"twoHundredDayAverage":4.02,"beta":2.36,"enterpriseValue":569634048,"forwardPE":-3.6,"priceToBook":4.63,"priceToSales":141.71,"enterpriseToRevenue":141.21,"enterpriseToEbitda":-2.86,"pegRatio":0,"ebitda":-199135008,"ebitdaMargin":0,"freeCashflow":-78317504,"operatingCashflow":-156416992,"totalDebt":114512000,"debtToEquity":149.3,"currentRatio":3.8,"returnOnAssets":-41.5,"returnOnEquity":-216.1,"analystRating":"1.7 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":6.92,"targetHighPrice":11,"targetLowPrice":4.25,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":23.8,"institutionHeldPercent":65.9,"sharesOutstanding":180617451,"floatShares":107324696,"sharesShort":30352640,"shortRatio":16.36,"shortPercentOfFloat":16.8,"epsTrailing":-1.23,"epsForward":-0.87,"revenuePerShare":0.03,"bookValue":0.68,"officers":[{"age":46,"name":"Mr. Jeffrey D. Marrazzo M.B.A., M.P.A.","title":"Executive Chair"},{"age":50,"name":"Dr. Allan  Reine M.D.","title":"CEO & Director"},{"age":63,"name":"Dr. Ann L. Lee Ph.D.","title":"Chief Technical Officer"},{"age":71,"name":"Dr. Keith Michael Gottesdiener M.D., Ph.D.","title":"Consultant"},{"age":38,"name":"Dr. Andrew  Anzalone M.D., Ph.D.","title":"Co-Founder"},{"age":null,"name":"Dr. David R. Liu Ph.D.","title":"Co-Founder & Member of Scientific Advisory Board"},{"age":41,"name":"Ms. Svetlana  Makhni","title":"Chief Financial Officer"},{"age":46,"name":"Mr. Ryan E. Brown J.D.","title":"Chief Legal Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://primemedicine.com","phone":"617 465 0013"}}